Browsing Tag
ABRYSVO
4 posts
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
ACIP expands Pfizer’s ABRYSVO vaccine guidance to include at-risk adults aged 50–59
Pfizer's RSV vaccine ABRYSVO now recommended for at-risk adults aged 50–59. Learn what it means for public health and Pfizer’s expanding vaccine portfolio.
EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for ABRYSVO, its bivalent respiratory syncytial…
FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV
The US Food and Drug Administration (FDA) has granted approval to Pfizer Inc.’s ABRYSVO, a bivalent Respiratory Syncytial…